Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9577539 | 0.89 | ALOX5 (0.54) | KMT2ASMN1; SMN2FFAR1MAOBALOX5 | |
| SCHEMBL8770884 | 0.88 | KMT2A (0.60) | KMT2ASMN1; SMN2MAOBALOX5L3MBTL1 | |
| SCHEMBL232540 | 0.86 | LMNA (0.59) | FFAR1MAOBALOX5L3MBTL1LMNA | |
| SCHEMBL17700119 | 0.86 | KMT2A (0.55) | KMT2ASMN1; SMN2FFAR1MAOBALOX5 | |
| SCHEMBL8771185 | 0.84 | SMN1; SMN2 (0.73) | KMT2ASMN1; SMN2FFAR1MAOBALOX5 | |
| SCHEMBL8770948 | 0.84 | KMT2A (0.56) | KMT2ASMN1; SMN2MAOBALOX5L3MBTL1 | |
| SCHEMBL3443228 | 0.82 | SMN1; SMN2 (0.66) | KMT2ASMN1; SMN2MAOBALOX5L3MBTL1 | |
| SCHEMBL8770878 | 0.82 | L3MBTL1 (0.68) | L3MBTL1ALDH1A1 | |
| SCHEMBL4596162 | 0.82 | KMT2A (0.57) | KMT2ASMN1; SMN2MAOBALOX5LMNA | |
| SCHEMBL20816018 | 0.82 | KMT2A (0.57) | KMT2ASMN1; SMN2MAOBALOX5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10081615-B2 | Sulfamate derivative compounds for use in treating or alleviating pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-09-25 | — | — | US | disclosed |
| EP-3031799-B1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| EP-3079687-B1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS CO LTD (KR) | 2018-02-28 | — | — | EP | disclosed |
| US-9776962-B2 | Aromatic compounds with GPR40 agonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20160311792-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-10-27 | — | — | US | disclosed |
| EP-3079687-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | Bio-Pharm Solutions Co., Ltd. (KR) | 2016-10-19 | — | — | EP | disclosed |
| EP-3031799-A1 | AROMATIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-15 | — | — | EP | disclosed |
| US-20160115128-A1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-28 | — | — | US | disclosed |
| WO-2015088272-A9 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015088272-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-06-18 | — | — | WO | disclosed |
| EP-0451668-B1 | Process for the production of optically active alkyl 3-aryl-3-hydroxypropionates | CHISSO CORP (JP) | 1997-08-13 | — | — | EP | disclosed |
| US-5214069-A | Lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-05-25 | — | — | US | disclosed |
| US-5202457-A | Enzyme catalyzed transesterification, resolution of optical active alkyl 3-aryl-3-hydroxypropionate | CHISSO CORPORATION (JP) | 1993-04-13 | — | — | US | disclosed |
| US-5132328-A | Lipoxygenase inhibitors as antiinflammatory agents or antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-21 | — | — | US | disclosed |
| EP-0451668-A2 | Optically active alkyl 3-aryl-3-hydroxypropionates and a method for producing thereof | CHISSO CORPORATION (JP) | 1991-10-16 | — | — | EP | disclosed |
| EP-0375368-A2 | Alcohol and ether derivatives | ZENECA LIMITED (GB) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115128-A1 | AROMATIC COMPOUND | GLP1R, GPR119, GPR39 | KMT2A 1359/4885SMN1; SMN2 1516/4885FFAR1 52/4885 |
| US-20160311792-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | SULT2A1, SULT1A1, TRPV1 | KMT2A 1146/4885SMN1; SMN2 465/4885FFAR1 2367/4885 |
| US-10081615-B2 | Sulfamate derivative compounds for use in treating or alleviating pain | SULT2A1, SULT1A1, TRPV1 | KMT2A 1146/4885SMN1; SMN2 465/4885FFAR1 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.